The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism
- Supplementary File 1:
PDF-Document (PDF, 1034 KiB)
Konger, R.L.; Derr-Yellin, E.; Ermatov, N.; Ren, L.; Sahu, R.P. The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism. Molecules 2019, 24, 2192. https://doi.org/10.3390/molecules24112192
Konger RL, Derr-Yellin E, Ermatov N, Ren L, Sahu RP. The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism. Molecules. 2019; 24(11):2192. https://doi.org/10.3390/molecules24112192
Chicago/Turabian StyleKonger, Raymond L.; Derr-Yellin, Ethel; Ermatov, Nurmukambed; Ren, Lu; Sahu, Ravi P. 2019. "The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism" Molecules 24, no. 11: 2192. https://doi.org/10.3390/molecules24112192